|
Causes of hospitalization among people living with HIV: a global review
|
|
0
|
581
|
September 28, 2017
|
|
WHO confirms antiretroviral therapy reduces the risk of life-threatening HIV-related infections
|
|
0
|
503
|
September 28, 2017
|
|
Review of Temporary Recommendation
|
|
0
|
633
|
September 27, 2017
|
|
Statement of the 13th IHR Emergency Committee regarding the international spread of poliovirus
|
|
0
|
514
|
September 27, 2017
|
|
General elect welcomes new funding for polio eradication
|
|
0
|
576
|
September 27, 2017
|
|
States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPV
|
|
0
|
533
|
September 27, 2017
|
|
Statement of the 14th IHR Emergency Committee regarding the international spread of poliovirus
|
|
0
|
421
|
September 27, 2017
|
|
A global research agenda for paediatric HIV
|
|
0
|
474
|
September 26, 2017
|
|
Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at "substantial" risk
|
|
0
|
417
|
September 26, 2017
|
|
World Health Organization Guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach
|
|
0
|
386
|
September 26, 2017
|
|
The strategic use of antiretrovirals to prevent HIV infection: a converging agenda
|
|
0
|
427
|
September 26, 2017
|
|
Malawi villagers embrace HIV self-testing
|
|
0
|
437
|
September 26, 2017
|
|
WHO report on inequalities in childhood immunisation rewarded by the British Medical Association
|
|
0
|
465
|
September 25, 2017
|
|
Breakthrough for men’s health: WHO and experts kick off development of strategy and report
|
|
0
|
400
|
September 25, 2017
|
|
Frequently asked questions on migration
|
|
0
|
394
|
September 25, 2017
|
|
Health and sexual diversity
|
|
0
|
414
|
September 25, 2017
|
|
Advancing health through attention to gender, equity and human rights
|
|
0
|
433
|
September 25, 2017
|
|
Programmatic and public health implications of misdiagnosis of HIV
|
|
0
|
419
|
September 23, 2017
|
|
When will WHO update this information in our guidelines?
|
|
0
|
367
|
September 23, 2017
|
|
What is WHO’s position on the use of EFV400?
|
|
0
|
383
|
September 23, 2017
|
|
What is the potential impact of reduced DTG?
|
|
0
|
398
|
September 23, 2017
|
|
What is the potential impact of reduced DTG pricing?
|
|
0
|
353
|
September 23, 2017
|
|
Can we use DTG to treat HIV among infants, children and adolescents?
|
|
0
|
382
|
September 23, 2017
|
|
Do we have enough active pharmaceutical ingredients for all people in need of DTG?
|
|
0
|
397
|
September 23, 2017
|
|
What is the regulatory status of DTG?
|
|
0
|
466
|
September 22, 2017
|
|
What are the unanswered questions about DTG safety and efficacy? When will we know these answers?
|
|
0
|
451
|
September 22, 2017
|
|
Is DTG recommended as part of the WHO ARV guidelines? Since when?
|
|
0
|
527
|
September 22, 2017
|
|
New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low- and middle-income countries at reduced price
|
|
0
|
376
|
September 22, 2017
|
|
Transition to the use of dolutegravir
|
|
0
|
386
|
September 22, 2017
|
|
The evolving role of CD4 cell counts in HIV care
|
|
0
|
433
|
September 21, 2017
|